Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1 G2032R and ALK G1202R
Journal of Enzyme Inhibition and Medicinal Chemistry · 2023
DOI: 10.1080/14756366.2023.2227779 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, 2023. Verfasst von Siming Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medicinal University (Foshan Maternity & Child Healthcare Hospital), Foshan, China. Hauptthemen laut MEDLINE: Protein-Tyrosine Kinases, Lung Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: China postdoctoral Science Foundation, Natural Science Foundation of Guangdong Province, Key Research and Development Plan of Guangzhou.
Abstract (Originalsprache)
Clinical treatment by FDA-approved ROS1/ALK inhibitor Crizotinib significantly improved the therapeutic outcomes. However, the emergence of drug resistance, especially driven by acquired mutations, have become an inevitable problem and worsened the clinical effects of Crizotinib. To combat drug resistance, some novel 2-aminopyridine derivatives were designed rationally based on molecular simulation, then synthesised and subjected to biological test. The preferred spiro derivative C01 exhibited remarkable activity against CD74-ROS1G2032R cell with an IC50 value of 42.3 nM, which was about 30-fold more potent than Crizotinib. Moreover, C01 also potently inhibited enzymatic activity against clinically Crizotinib-resistant ALKG1202R, harbouring a 10-fold potency superior to Crizotinib. Furthermore, molecular dynamic disclosed that introducing the spiro group could reduce the steric hindrance with bulky side chain (Arginine) in solvent region of ROS1G2032R, which explained the sensitivity of C01 to drug-resistant mutant. These results indicated a path forward for the generation of anti Crizotinib-resistant ROS1/ALK dual inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medicinal University (Foshan Maternity & Child Healthcare Hospital), Foshan, China.
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Förderung
- China postdoctoral Science Foundation
- Natural Science Foundation of Guangdong Province
- Key Research and Development Plan of Guangzhou
Zitieren
APA
Liu, S., Huang, C., Huang, C., Huang, Y., Yu, Y., Wu, G., Guo, F., Jiang, Y., Wan, S., Zhu, Z., Tian, Y., Zhu, J., & Zhang, J. (2023). Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1 G2032R and ALK G1202R. Journal of Enzyme Inhibition and Medicinal Chemistry. https://doi.org/10.1080/14756366.2023.2227779
Vancouver
Liu S, Huang C, Huang C, Huang Y, Yu Y, Wu G, et al. Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1 G2032R and ALK G1202R. Journal of Enzyme Inhibition and Medicinal Chemistry. 2023. doi:10.1080/14756366.2023.2227779
BibTeX
@article{Liu2023,
author = {Liu, Siming and Huang, Chuan and Huang, Chunhui and Huang, Yaqi and Yu, Yonghuan and Wu, Guowu and Guo, Fengqiu and Jiang, Ying and Wan, Shanhe and Zhu, Zhengguang and Tian, Yuanxin and Zhu, Jianghua and Zhang, Jiajie},
title = {Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1 G2032R and ALK G1202R},
journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
year = {2023},
doi = {10.1080/14756366.2023.2227779}
}
EUVIMED